AIM
TXG icon

Aigen Investment Management’s 10x Genomics TXG Stock Holding History

Aigen Investment Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,734
Closed -$515K – 1023
2024
Q1 		$515K Buy
13,734
+7,440
+118% +$327K 0.11% 273
2023
Q4 		$352K Sell
6,294
-12,227
-66% -$532K 0.06% 440
2023
Q3 		$764K Buy
+18,521
New +$963K 0.14% 231
2022
Q1 		– Sell
-4,765
Closed -$675K – 1090
2021
Q4 		$675K Buy
+4,765
New +$730K 0.04% 537
2021
Q1 		– Sell
-11,392
Closed -$1.61M – 892
2020
Q4 		$1.61M Buy
+11,392
New +$1.65M 0.21% 119

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Aigen Investment Management's TXG Position: Q2 2024 in Review

Aigen Investment Management sold out of 10x Genomics (TXG) in Q2 2024, closing a stake of 13,734 shares — an estimated $515K sold.

Aigen Investment Management first reported a position in TXG in Q4 2020 and held it in 5 quarters. The position peaked at $1.61M in Q4 2020. 261 funds tracked by Wall St. Rank hold TXG as of Q2 2024.

  • Aigen Investment Management reported no remaining 10x Genomics position as of Q2 2024 after selling out during the quarter.
  • Aigen Investment Management sold 13,734 10x Genomics shares in Q2 2024, an estimated $515K.
  • Aigen Investment Management first reported a position in 10x Genomics in Q4 2020 and held it in 5 quarters.
  • Aigen Investment Management's 10x Genomics position peaked at $1.61M in Q4 2020.
  • 261 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2024.

Based on Aigen Investment Management's 13F filing for Q2 2024, filed 9 Aug 2024.